| 6B0F: reference: Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer., Tria GS, Abrams T, Baird J, Burks HE, Firestone B, Gaither LA, Hamann LG, He G, Kirby CA, Kim S, Lombardo F, Macchi KJ, McDonnell DP, Mishina Y, Norris JD, Nunez J, Springer C, Sun Y, Thomsen NM, Wang C, Wang J, Yu B, Tiong-Yip CL, Peukert S, J Med Chem. 2018 Mar 22. doi: 10.1021/acs.jmedchem.7b01682. PMID: 29562737 |
This OCA 
Structure page
uses Jmol,
developed by the Jmol Development Team
(documentation).